ライフサイエンスコーパス: organ transplantation

1 se of weight limits (ie, orthopedic surgery, organ transplantation).

2 echnique has gained interest in the field of organ transplantation.

3 enous drug use, radiation therapy, and solid organ transplantation.

4 r systemic immunosuppression in VCA or solid organ transplantation.

5 and vaccination of all patients before solid organ transplantation.

6 of degenerative, autoimmune diseases and for organ transplantation.

7 which may lead to liver failure and need for organ transplantation.

8 correlation with long-term survival in solid organ transplantation.

9 vel immunosuppressive drugs for use in solid organ transplantation.

10 ency virus (HIV) patients have had access to organ transplantation.

11 of being physically active) following solid organ transplantation.

12 Allograft tolerance is the ultimate goal of organ transplantation.

13 stein-Barr virus (EBV) infection after solid organ transplantation.

14 opoietic stem cell transplantation and solid organ transplantation.

15 o cure chronic hepatitis E in the setting of organ transplantation.

16 onor or recipient cell therapy combined with organ transplantation.

17 ions in other pathological conditions beyond organ transplantation.

18 elopment of immunoregulation following solid organ transplantation.

19 osuppressive drug target in autoimmunity and organ transplantation.

20 treating hypoxic-ischemic human diseases and organ transplantation.

21 ent and its effect on the immune response to organ transplantation.

22 risk of skin cancer, particularly SCC, after organ transplantation.

23 Diarrhea is a frequent complication of solid organ transplantation.

24 s to allografts represent a major barrier in organ transplantation.

25 e effect of aging and the immune response to organ transplantation.

26 imary cause of long-term graft failure after organ transplantation.

27 ly applicable refinement of Treg therapy for organ transplantation.

28 ased age, white race, male sex, and thoracic organ transplantation.

29 s the most common malignancy occurring after organ transplantation.

30 n the cellular and humoral response in solid organ transplantation.

31 henolate sodium, and it is widely used after organ transplantation.

32 matching improves graft survival rates after organ transplantation.

33 25-30 times greater in CF patients after an organ transplantation.

34 ng the organ supply/demand mismatch in solid organ transplantation.

35 s in HLA antibody responses and matching for organ transplantation.

36 regarding the use of social media to foster organ transplantation.

37 esis of ischemia-reperfusion injury in solid organ transplantation.

38 g those associated with bone marrow or solid organ transplantation.

39 ns of reducing allograft rejection following organ transplantation.

40 les in ocular surface immunity and allogenic organ transplantation.

41 s and opportunities in contemporary clinical organ transplantation.

42 s and solutions to the current challenges in organ transplantation.

43 potential uses of nanotechnology in cell and organ transplantation.

44 fted tissues are the major reason for failed organ transplantation.

45 , prenatal diagnosis, infectious diseases or organ transplantation.

46 ns of this novel MPS classification in solid organ transplantation.

47 tions for this malignancy-tumor resection or organ transplantation.

48 patients who are not considered eligible for organ transplantation.

49 outcomes associated with smoking after solid organ transplantation.

50 HHV-8)-related disease described after solid organ transplantation.

51 outcomes with novel perfusion strategies in organ transplantation.

52 fter allogeneic hematopoietic cell and solid organ transplantation.

53 tious diseases, and it has also been used in organ transplantation.

54 ful monitoring tool in cancer, pregnancy and organ transplantation.

55 provides an alternative pathway to deceased organ transplantation.

56 cess of ischemia-reperfusion injury (IRI) in organ transplantation.

57 itions but has only recently been applied to organ transplantation.

58 is improving long-term outcomes after solid organ transplantation.

59 ted rejection and graft loss after all solid organ transplantation.

60 lograft survival and unmet clinical needs in organ transplantation.

61 he main obstacle in the long-term success of organ transplantation.

62 A) is recommended in patients awaiting solid organ transplantation.

63 immunodeficiency virus (HIV)-caused AIDS and organ transplantation.

64 ental illness (SMI) a significant concern in organ transplantation.

65 enge limiting allograft survival after solid organ transplantation.

66 ight into how to achieve immune tolerance in organ transplantation.

67 in myocardial infarction, stroke, and solid organ transplantation.

68 incidence of cancer is increased after solid organ transplantation.

69 gnificant role in graft survival after solid organ transplantation.

70 ytomegalovirus (CMV) replication after solid organ transplantation.

71 r controlling antibody-mediated rejection in organ transplantation.

72 ation, remains the major problem in clinical organ transplantation.

73 olved in post-I/R injuries as observed after organ transplantation.

74 infrequent but serious complication of solid organ transplantation.

75 been widely used to prevent rejection after organ transplantation.

76 ion of nitric oxide inhibition reduce IRI in organ transplantation.

77 to prevent rejection and graft loss in solid organ transplantation.

78 patients who have undergone or will undergo organ transplantation.

79 aft loss in most (if not all) types of solid-organ transplantation.

80 of lymphatic vessels in the context of solid organ transplantation.

81 e impact of the current COVID-19 pandemic on organ transplantation.

82 detrimental T cell memory in the settings of organ transplantation.

83 ameliorates the consequences of IRI in solid organ transplantation.

84 use of such enzymes in blood conversion and organ transplantation.

85 onor or recipient cell therapy combined with organ transplantation.

86 e risk of transmission of SARS-CoV-2 through organ transplantation.

87 patients who have undergone or will undergo organ transplantation.

88 pression minimization or withdrawal in solid organ transplantation.

89 nosis and personalized therapeutics in solid organ transplantation.

90 ogy, and immune suppression have transformed organ transplantation.

91 ch for reducing general immunosuppression in organ transplantation.

92 opment for risk assessment in the setting of organ transplantation.

93 e the role of MP therapeutic agents in solid organ transplantation.

94 ing approach for the ex situ preservation in organ transplantation.

95 also as an unavoidable consequence of solid organ transplantation.

96 nor to recipient remains an inherent risk of organ transplantation.

97 lation is an early marker of injury in solid organ transplantation.

98 s a risk factor for graft rejection in solid organ transplantation.

99 ing stroke, myocardial infarction, and solid organ transplantation.

100 tems have successfully been applied in solid organ transplantations.

101 always mimic those of the well-studied solid organ transplantations.

102 cal achievements including cancer therapy or organ transplantations.

103 e prospective multicenter Clinical Trials in Organ Transplantation-04 study.

104 subjects enrolled in the Clinical Trials in Organ Transplantation-09 study in which we randomized st

105 The Clinical Trials in Organ Transplantation-09 Trial was a randomized, prospec

106 Cardiac Transplantation [Clinical Trials in Organ Transplantation-11]) study was a randomized, place

107 This trial, Clinical Trials in Organ Transplantation 16 (CTOT-16), sought to evaluate n

108 13 318 eligible survivors, 100 had 103 solid organ transplantations (50 kidney, 37 heart, nine liver,

109 d immunologic tolerance" and eventually made organ transplantation a reality.

110 rrent immunosuppressive therapies applied to organ transplantations affect the wide array of Treg pop

111 ate legislation propose to address access to organ transplantation among unauthorized immigrants.

112 n on a waiting list for or receiving a solid organ transplantation and 5-year survival following thes

113 that is widely used for immunosuppression in organ transplantation and autoimmune diseases, as well a

114 f a complex diagnosis especially after solid organ transplantation and can lead to difficulties in fi

115 PML, but many modern treatments for cancers, organ transplantation and chronic inflammatory disease c

116 end-organ failure through greater access to organ transplantation and decreased waitlist mortality r

117 responses in a variety of models, including organ transplantation and graft versus host disease (GVH

118 the prevention and treatment of TB in solid organ transplantation and hematopoietic stem cell transp

119 Our findings inform organ transplantation and hepatic immunotherapy, reveali

120 about the T cell response because it governs organ transplantation and hinders the discovery of disea

121 immunocompromised patients, in particular in organ transplantation and in stem cell therapy.

122 d with rejection and allograft loss in solid organ transplantation and may act synergistically with H

123 periocular region represents a risk of solid organ transplantation and may produce significant ocular

124 The disparity between patients awaiting organ transplantation and organ availability increases e

125 ility between patient and donor before solid organ transplantation and preventing hyperacute rejectio

126 therapies to modulate the immune response in organ transplantation and repair tissues after acute or

127 The demand for organ transplantation and repair, coupled with a shortag

128 iciency virus (HIV)-positive persons seeking organ transplantation and serving as organ donors for HI

129 to oral calcineurin inhibitors used in solid-organ transplantation and spontaneous reporting of malig

130 ption of a pathogenic role for NETs in solid organ transplantation and suggest that NETs are a promis

131 cal settings, including (but not limited to) organ transplantation and the treatment of autoimmune di

132 The largest reductions in solid organ transplantation and waitlist deaths were seen in k

133 used to prolong allograft survival in solid organ transplantations and have been shown to be superio

134 ons beyond oncology, in infectious diseases, organ transplantation, and autoimmunity.

135 hma, autoimmune diseases, tumor development, organ transplantation, and chronic infections during the

136 nd chronic rejection in the context of solid organ transplantation, and emerging evidence suggests th

137 ver disease, lung disease, malignancy, other organ transplantation, and human immunodeficiency virus

138 e rejection remains a significant problem in organ transplantation, and lymphatic and blood vessels a

139 g from smoking cessation and healthy diet to organ transplantation, and most of all condemnation of h

140 revalent infectious complication after solid organ transplantation, and recipients of isolated intest

141 ldbearing age, toddlers, recipients of solid organ transplantation, and stem cell transplant patients

142 equired in hematopoietic stem cell and solid-organ transplantation, and the histocompatibility comple

143 influenced by cardiovascular disease, other organ transplantation, and the total comorbidity scores.

144 MNA is a modifiable risk factor after organ transplantation, and treatment is most effective i

145 or antibody reduction before and after solid organ transplantation are considered, to better understa

146 vely assess viability of marginal grafts for organ transplantation are currently lacking.

147 Systemic treatments beyond organ transplantation are lacking for these diseases.

148 or use of the latter in the setting of solid organ transplantation are presented in the accompanying

149 Organ transplantation as an option to overcome end-stage

150 The concept of organ transplantation as treatment for complex genetic c

151 atitis E represents an emerging challenge in organ transplantation, as there are currently no establi

152 lly higher multiplicity of infection seen in organ transplantation-associated HCV acquisition.

153 s, including those for bone marrow and solid organ transplantation, autoimmune diseases, and tissue a

154 opoietic stem cell transplantation, or solid organ transplantation be screened for active or prior he

155 Jan 1, 1970, and Dec 31, 1986 (without solid organ transplantation before cohort entry) to the Organ

156 A total of 3489 patients underwent solid organ transplantation between 1990 and 2008.

157 ompted by the recent completion of the first organ transplantation between HIV-infected persons in Ca

158 nt demonstration of the short term safety of organ transplantation between HIV-infected persons promp

159 is of adult patients who underwent abdominal organ transplantation between January 1, 2008, and Decem

160 o close the gap between demand and supply in organ transplantation but are associated with age-specif

161 ed with morbidity and mortality in abdominal organ transplantation but has not been examined in lung

162 e are important components to the success of organ transplantation, but are also associated with adve

163 ssive weight (EW) gain is common after solid organ transplantation, but there is little information c

164 ressant, accelerates onset of diabetes after organ transplantation, but underlying molecular mechanis

165 In the setting of solid-organ transplantation, calcineurin inhibitor (CNI)-based

166 Two-year follow-up demonstrates that organ transplantation can halt life-threating recurrent

167 The study was conducted in a large organ transplantation center that serves the entire Norw

168 Outcomes after solid organ transplantation continue to improve, but premature

169 wever, the number of patients awaiting solid organ transplantation continues to remain much higher th

170 withdrawal (ITN030ST) and Clinical Trials in Organ Transplantation (CTOT-03) studies.

171 sepsis (CV = 1.37) and among the lowest for organ transplantation (CV </= 0.43).

172 In organ transplantation, delayed graft function (DGF) rema

173 Solid organ transplantation disrupts virus-host relationships,

174 In solid organ transplantation, donor-derived immune cells are as

175 quate testing capacity can support continued organ transplantation, even in a SARS-CoV-2 hyperendemic

176 ID-19) pandemic to continue lifesaving solid organ transplantation for heart, lung, liver, and kidney

177 ions on necessary future studies to optimize organ transplantation for older people.

178 tients who were HCV negative underwent solid organ transplantation from a donor who was HCV viremic.

179 Organ transplantation from ABO blood group-incompatible

180 Existing legislation allows organ transplantation from an HIV-infected donor under e

181 ct to safety for recipients undergoing solid-organ transplantation from donors with a history of fata

182 Solid organ transplantation from hepatitis C virus-positive (H

183 y review considerations related to advancing organ transplantation from HIV-infected donors in Canada

184 em cell transplant cohort and excluded solid-organ transplantation from this cohort.

185 HIV-infected persons undergoing organ transplantation generally achieve comparable patie

186 The Saudi Center for Organ Transplantation has been established in 1985 as a

187 Their role in organ transplantation has been poorly defined due to con

188 Allergy transfer upon solid organ transplantation has been reported in the literatur

189 The risk of SCC after organ transplantation has declined significantly since t

190 Emerging knowledge regarding B cells in organ transplantation has demonstrated that these cells

191 Development of amyloidosis post solid-organ transplantation has not been reported, although pl

192 Investigation of these processes in clinical organ transplantation has, however, been hampered by the

193 laced on a waiting list or receiving a solid organ transplantation, hazard ratios (HRs) for identifie

194 As with solid organ transplantation, however, rejection must be contro

195 erlying immunosuppression such as, diabetes, organ transplantation, Human immunodeficiency virus (HIV

196 se of a novel procedure called ischemia-free organ transplantation (IFOT) for patients with end-stage

197 After solid organ transplantation, immune-mediated rejection mandate

198 e oral cavity, which may develop after solid organ transplantation in children.

199 ld in health sciences has more interest than organ transplantation in fostering progress in regenerat

200 he National Institutes of Health (NIH) Solid Organ Transplantation in HIV Trial, reflecting experienc

201 cohort study of patients who underwent solid-organ transplantation in Ontario, Canada, between 1991 a

202 produced functional bioengineered livers for organ transplantation in preclinical studies.

203 Pregnancy resembles organ transplantation in that the fetus, possessing pate

204 Organ transplantation in the KSA has made great strides

205 n, introduced in 2013, will further increase organ transplantation in the UK.

206 impact of coronavirus disease 2019 on solid organ transplantation in the United States has not been

207 roles of ageing, sex, the gut microbiome and organ transplantation in this complex interplay are also

208 For organ transplantation, in particular, the loss of lifesa

209 treatment may improve recipient outcomes in organ transplantation; in this analysis, we aimed to det

210 posures were associated with increased solid organ transplantation incidence.

211 In organ transplantation, infection and rejection are major

212 Organ transplantation into sensitized patients with pree

213 ft and host in both directions, showing that organ transplantation involves implantation of both the

214 Solid organ transplantation is a curative therapy for hundreds

215 Solid organ transplantation is a lifesaving therapy for patien

216 The high risk of skin cancer after organ transplantation is a major clinical challenge and

217 Although organ transplantation is an effective therapy for older

218 Tobacco use after solid organ transplantation is associated with allograft dysfu

219 Cytomegalovirus (CMV) infection in solid-organ transplantation is associated with increased morbi

220 Acute kidney injury after nonrenal solid organ transplantation is associated with prolonged lengt

221 Medication nonadherence (MNA) after solid organ transplantation is highly prevalent and associated

222 -stage chronic kidney disease, the option of organ transplantation is limited because of the scarce a

223 rimary risks of HIV-positive to HIV-positive organ transplantation is loss of virological control bec

224 The field of abdominal organ transplantation is multifaceted, with the clinicia

225 ver, using ID as a contraindication to solid organ transplantation is not evidence-based and reduces

226 h concern; however, the incidence post solid-organ transplantation is not well reported.

227 Organ transplantation is now a preferred treatment for e

228 Organ transplantation is often lifesaving, but the long-

229 ABO-incompatible (ABOi) organ transplantation is performed owing to unremitting

230 Saudi Center for Organ Transplantation is playing a central role in all a

231 Despite optimization of these variables, organ transplantation is still often plagued by substant

232 Organ transplantation is the most successful treatment f

233 Solid organ transplantation is the preferred treatment for pat

234 Solid organ transplantation is uncommon in ageing childhood ca

235 The field of solid organ transplantation is unique in the breadth of the st

236 Severe B-lineage PTLD after solid organ transplantation may be classified as SR or HR and

237 plotype B from viral replication after solid organ transplantation may extend beyond CMV to other her

238 loning will bring enhanced possibilities for organ transplantation, nerve cells and tissue healing, a

239 iency virus (HIV)/AIDS, cancer, stem cell or organ transplantation, nonsteroid immunosuppressive ther

240 ing strategy to induce tolerance after solid-organ transplantation or prevent graft-versus-host disea

241 12), radiation therapy (OR, 5.28), and solid organ transplantation (OR, 2.48) increased the risk of s

242 e now being translated to the field of solid organ transplantation, particularly for livers and kidne

243 erum samples obtained from nonselected solid-organ transplantation patients suffering from probable,

244 support exclusion of pulmonary IFI in solid-organ transplantation patients, the low positive predict

245 Previously treatable only by organ transplantation, pharmaceutical therapy that slows

246 Current immunosuppression regimens in organ transplantation primarily inhibit T cells.

247 ir-pibrentasvir therapy results in expedited organ transplantation, rapid HCV suppression, prevention

248 In solid organ transplantation recipients, exercise is able to im

249 idely used as standard immunosuppressants in organ transplantation recipients.

250 Solid organ transplantation reduces both morbidity and mortali

251 Successful solid organ transplantation reflects meticulous attention to t

252 ecific antibodies, conclusions made in solid organ transplantation regarding antibody-mediated reject

253 We used the Dutch Organ Transplantation Registry to include recipients (>/

254 From the Dutch Organ Transplantation Registry, we selected 3597 recipie

255 Mitigating therapies, aside from impractical organ transplantation, remain limited and the possibilit

256 pport self-management, but evidence in solid organ transplantation remains unclear.

257 In most solid organ transplantation settings, the role of NK cells is

258 preclinical models and experiences in human organ transplantation should allow for optimization of t

259 Survival outcomes showed that solid organ transplantation should be considered for 5-year ch

260 ectively excluding patients with prior solid organ transplantation (SOT) and posttransplant lymphopro

261 fectively prevents CMV infection after solid organ transplantation (SOT) but is associated with high

262 Patients undergoing evaluation for solid organ transplantation (SOT) frequently have a history of

263 ction (CDI) treatment; however, use in solid organ transplantation (SOT) patients has theoretical saf

264 Information on solid organ transplantation (SOT) performed in pediatric recip

265 Immune measurements that distinguish solid organ transplantation (SOT) recipients who control cytom

266 evere infection (LI) beyond month 6 in solid organ transplantation (SOT) recipients.

267 tly, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and uncle

268 cytomegalovirus (CMV) infection after solid organ transplantation (SOT) requires a functional immune

269 ors, in regulating the alloresponse to solid organ transplantation (SOT).

270 tion is an ongoing clinical problem in solid-organ transplantation (SOT).

271 s an innovative cell-based approach in solid organ transplantation (SOT).

272 Organ transplantation started in the Kingdom of Saudi Ar

273 Organ scarcity continues in solid organ transplantation, such that the availability of org

274 and infectious challenges accompanying solid organ transplantation, susceptibility to post-transplant

275 sizing the parallels between women and solid organ transplantation that could allow vaccines to be de

276 icle, we will consider some of the topics in organ transplantation that were discussed by the attende

277 Kaposi sarcoma (KS) can develop following organ transplantation through reactivation of recipient

278 KS can develop following organ transplantation through reactivation of the recipi

279 , we propose to use the experience gained in organ transplantation to shed light on the path that sha

280 extensively by investigators in the field of organ transplantation to study the rejection process, te

281 ve helped to shape the ethical boundaries of organ transplantation today.

282 A consensus conference on frailty in solid organ transplantation took place on February 11, 2018, t

283 Organ transplantation (Tx) is a risk factor for Clostrid

284 5-year overall survival after solid organ transplantation was 93.5% (95% CI 81.0-97.9) for k

285 on-based cancer cohort, we evaluated whether organ transplantation was associated with worse prognosi

286 The SMR for cancer death after solid-organ transplantation was higher in children (SMR, 84.61

287 Solid-organ transplantation was identified using the national

288 n, haematological malignancies, and previous organ transplantation were excluded).

289 eview, the potential of RNAi in the field of organ transplantation will be discussed.

290 re of no other field more than the future of organ transplantation will be forged by progress occurri

291 Many children who have undergone solid organ transplantation will require additional support in

292 al research on stem cells, tissues, or solid organ transplantation with >=20 participants, which ment

293 evelopments in tolerance induction for solid organ transplantation with a particular emphasis on chim

294 Balamuthia can be transmitted through organ transplantation with an observed incubation time o

295 ggests that amyloidosis may occur post solid-organ transplantation with an overall poor survival.

296 ow) regulatory T cells (Tregs) in a model of organ transplantation with CD40Ig could be abrogated by

297 s, offering ideas to improve safety in solid organ transplantation with limited health care resources

298 and everolimus, are increasingly used after organ transplantation with potential advantages in virus

299 Seventy-four cases of PTLD after solid organ transplantation with sufficient material for furth

300 ts, showing potential applications for solid organ transplantation without immune suppression.